×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/13
07:00 am
enta
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Low
Report
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
4/7
07:00 am
enta
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Low
Report
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
3/30
07:24 am
enta
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) [Yahoo! Finance]
Neutral
Report
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) [Yahoo! Finance]
3/30
07:00 am
enta
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Neutral
Report
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
3/26
09:00 am
enta
Enanta Pharmaceuticals (ENTA) is now covered by Rodman & Renshaw. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (ENTA) is now covered by Rodman & Renshaw. They set a "buy" rating and a $20.00 price target on the stock.
3/15
06:50 pm
enta
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]
3/3
07:00 am
enta
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Low
Report
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
2/10
08:05 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
06:07 pm
enta
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: VANGUARD GROUP INC
3/26
08:00 am
enta
Form 8-K ENANTA PHARMACEUTICALS For: Mar 20
High
Report
Form 8-K ENANTA PHARMACEUTICALS For: Mar 20
3/13
04:21 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Vance Terry
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Vance Terry
3/13
04:20 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Russell Lesley
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Russell Lesley
3/13
04:18 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Peterson Kristine
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Peterson Kristine
3/13
04:17 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Hata Yujiro S
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: Hata Yujiro S
3/13
04:16 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: FOLETTA MARK G
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: FOLETTA MARK G
3/13
04:14 pm
enta
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: CARTER BRUCE L A
Low
Report
Form 4 ENANTA PHARMACEUTICALS For: Mar 11 Filed by: CARTER BRUCE L A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Baird likes Enanta's potential in COVID-19, upgrades to Outperform [Seeking Alpha]
11.2%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
TOP News Decliners
3/14
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
-24.0%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: